Cargando…

Novel Derivatives of Eugenol as a New Class of PPARγ Agonists in Treating Inflammation: Design, Synthesis, SAR Analysis and In Vitro Anti-Inflammatory Activity

The main objective of this research was to develop novel compounds from readily accessed natural products especially eugenol with potential biological activity. Eugenol, the principal chemical constituent of clove (Eugenia caryophyllata) from the family Myrtaceae is renowned for its pharmacological...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anjum, Noor Fathima, Shanmugarajan, Dhivya, Prashantha Kumar, B. R., Faizan, Syed, Durai, Priya, Raju, Ruby Mariam, Javid, Saleem, Purohit, Madhusudan N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10180488/ https://www.ncbi.nlm.nih.gov/pubmed/37175309 http://dx.doi.org/10.3390/molecules28093899

Ejemplares similares

Novel derivatives of eugenol as potent anti-inflammatory agents via PPARγ agonism: rational design, synthesis, analysis, PPARγ protein binding assay and computational studies
por: Anjum, Noor Fathima, et al.
Publicado: (2022)

Discovery of Novel Myristic Acid Derivatives as N-Myristoyltransferase Inhibitors: Design, Synthesis, Analysis, Computational Studies and Antifungal Activity
por: Javid, Saleem, et al.
Publicado: (2023)

Design and Development of Novel Glitazones for Activation of PGC-1α Signaling Via PPAR-γ Agonism: A Promising Therapeutic Approach against Parkinson’s Disease
por: Prabhakaran, Prabitha, et al.
Publicado: (2023)

Curcumin to inhibit binding of spike glycoprotein to ACE2 receptors: computational modelling, simulations, and ADMET studies to explore curcuminoids against novel SARS-CoV-2 targets
por: Shanmugarajan, Dhivya, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Discovery of New PPARδ/γ Dual Agonist and PPARδ and γ Agonists
por: Maltarollo, Vinicius G., et al.
Publicado: (2015)

Novel glitazones as PPARγ agonists: molecular design, synthesis, glucose uptake activity and 3D QSAR studies
por: Mandal, Subhankar P., et al.
Publicado: (2018)

PPARγ Agonists: Blood Pressure and Edema
por: Blazer-Yost, Bonnie L.
Publicado: (2010)

PPARγ Agonists: Emergent Therapy in Endometriosis
por: Vallée, Alexandre, et al.
Publicado: (2021)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
por: Rogue, Alexandra, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
por: Tsukahara, Tamotsu
Publicado: (2012)

PPARγ Agonist Beyond Glucose Lowering Effect
por: Sugawara, Akira, et al.
Publicado: (2011)

Relaxation of human pulmonary arteries by PPARγ agonists
por: Kozłowska, Hanna, et al.
Publicado: (2013)

Biological Rationale for the Use of PPARγ Agonists in Glioblastoma
por: Ellis, Hayley Patricia, et al.
Publicado: (2014)

PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
por: Harnchoowong, Sarawin, et al.
Publicado: (2017)

PPARγ and Its Agonists in Chronic Kidney Disease
por: Ma, Yuhua, et al.
Publicado: (2020)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

PPAR-γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain Tumors
por: Lichtor, Terry, et al.
Publicado: (2008)

New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy
por: Jia, Zhanjun, et al.
Publicado: (2014)

Therapeutic potential of PPARγ natural agonists in liver diseases
por: Wu, Liwei, et al.
Publicado: (2020)

Dual PPAR α/γ Agonists: Continuing Cardiac Concerns
por: Balachandran, Karthik
Publicado: (2019)

Regulation of Glial Cell Functions by PPAR-γ Natural and Synthetic Agonists
por: Bernardo, Antonietta, et al.
Publicado: (2008)

PPARγ and Agonists against Cancer: Rational Design of Complementation Treatments
por: Veliceasa, Dorina, et al.
Publicado: (2008)

The Case for the Use of PPARγ Agonists as an Adjunctive Therapy for Cerebral Malaria
por: Serghides, Lena
Publicado: (2012)

Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPARγ agonist
por: Goto, Tsuyoshi, et al.
Publicado: (2011)

Honokiol: A non-adipogenic PPARγ agonist from nature()
por: Atanasov, Atanas G., et al.
Publicado: (2013)

PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
por: Vella, Veronica, et al.
Publicado: (2017)

Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts
por: Koo, Jun Bon, et al.
Publicado: (2017)

Synthesis and Biological Activity of Piperine Derivatives as Potential PPARγ Agonists
por: Wang, Yanli, et al.
Publicado: (2020)

Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes
por: Piątkowska-Chmiel, Iwona, et al.
Publicado: (2022)

Obesity and the microbiome in atopic dermatitis: Therapeutic implications for PPAR-γ agonists
por: McAleer, Jeremy P.
Publicado: (2023)

PPAR Agonists for the Prevention and Treatment of Lung Cancer
por: Lakshmi, Sowmya P., et al.
Publicado: (2017)

Screening of saponins and sapogenins from Medicago species as potential PPARγ agonists and X-ray structure of the complex PPARγ/caulophyllogenin
por: Montanari, Roberta, et al.
Publicado: (2016)

Advances in PPARs Molecular Dynamics and Glitazones as a Repurposing Therapeutic Strategy through Mitochondrial Redox Dynamics against Neurodegeneration
por: Durai, Priya, et al.
Publicado: (2022)

Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-Specific PPAR-γ –Knockout (CM-PGKO) Mice
por: Barbieri, Michelangela, et al.
Publicado: (2012)

Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists
por: Lecarpentier, Yves, et al.
Publicado: (2019)

The PPARγ Agonist Rosiglitazone Impairs Colonic Inflammation in Mice with Experimental Colitis
por: Ramakers, Julian D., et al.
Publicado: (2007)

The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
por: Swanson, Christine R, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4nka9erll5h97sqa70ivsdejh6